로딩 중…
지수 로딩 중…
Daesung Microbiological Labs. Co., Ltd.
036480· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩5,480-0.18%
2026-11-02
Financials
Valuation Metrics
Daesung Microbiological Labs. Co., Ltd.'s Market Cap is ₩208B. At end of 2025 it was ₩277B. Ranked #2239 of 2,410 in KR market (top 93%), #1477 of 1,631 on KOSDAQ (top 91%), #222 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 20.82B KRW | KR#2,239/2,410 Sec#222/231 |
| Revenue | 25.20B KRW | KR#2,086/2,410 Sec#148/231 |
| Net Income | 350.8M KRW | KR#1,526/2,410 Sec#105/231 |
| Total Assets | 57.23B KRW | KR#2,135/2,410 Sec#188/231 |
| Net Assets | 34.49B KRW | KR#2,126/2,410 Sec#186/231 |
| Employees | 139 | KR#1,380/2,410 Sec#110/231 |
| Value | ||
| P/E | 59.37x | KR#1,453/2,410 Sec#96/231 |
| P/B | 0.60x | KR#1,082/2,410 Sec#59/231 |
| P/S | 0.83x | KR#1,337/2,410 Sec#77/231 |
| FCF Yield | 5.06% | KR#876/2,410 Sec#50/231 |
| Profitability | ||
| ROE | 1.02% | KR#1,480/2,410 Sec#101/231 |
| ROA | 0.61% | KR#1,460/2,410 Sec#103/231 |
| Op. Margin | -2.65% | KR#1,760/2,410 Sec#119/231 |
| Revenue Growth | 2.86% | KR#1,325/2,410 Sec#132/231 |
| Financial Health | ||
| Debt Ratio | 65.93% | KR#1,164/2,410 Sec#140/231 |
| Total Debt | 19.00B KRW | KR#1,392/2,410 Sec#111/231 |
| FCF | 1.05B KRW | KR#1,141/2,410 Sec#85/231 |
| Cash | 2.84B KRW | KR#2,173/2,410 Sec#206/231 |
| Current Ratio | 3.51x | KR#457/2,410 Sec#69/231 |
| Dividend | ||
| Div. Yield | 1.37% | KR#1,060/2,410 Sec#58/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -24.41% | KR#1,258/2,410 Sec#91/231 |
| 1M Return | -9.57% | KR#852/2,410 Sec#91/231 |
| From 52W High | -50.00% | KR#1,102/2,410 Sec#86/231 |
| 1Y MDD | -44.53% | KR#726/2,410 Sec#52/231 |
| Trading | ||
| Volume | 7,315 shares | KR#2,312/2,410 Sec#228/231 |
| Trading Value | 39.8M KRW | KR#2,301/2,410 Sec#227/231 |
| Foreign Own. | 2.68% | KR#1,391/2,410 Sec#128/231 |
| Per Share | ||
| EPS | 92 KRW | KR#1,439/2,410 Sec#96/231 |
| BPS | 9,077 KRW | KR#1,064/2,410 Sec#73/231 |
Company Info
동사는 1968년 설립되어 60여년간 동물용의약품 전문기업으로 성장하고, 2000년 코스닥시장에 상장함. 예방백신, 항생제 등 150여종 의약품을 제조·판매하며, 국내 200여개 대리점 직접판매와 조달청 납품, 6개국 수출로 내수 74%, 수출 26% 구성 보임. 신규시설 투자로 선진국 시장 진출 성장동력 확보하고, 질병 트렌드 맞춤 신제품 개발과 해외시장 공략으로 글로벌 경쟁력 강화 추구하고 있음. 대성미생물는 1966년에 설립되었으며 경기도 의왕시에 본사를 두고 있습니다.